AstraZeneca, Allergan Complete Pact for Crohn’s Disease Drug
By

AstraZeneca has completed the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan, for the global rights to MEDI2070, a biologic candidate being developed for Crohn’s disease. The candidate is an interleukin-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease and is ready for Phase II studies for ulcerative colitis, both of which are diseases outside AstraZeneca’s three main therapy areas. As a result, AstraZeneca will not retain a significant ongoing interest in MEDI2070.

Source: AstraZeneca 

Leave a Reply

Your email address will not be published.